Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The impact of HIV drug resistance testing on changes to treatment.

AIDS (London, England) - 13 Mar 2011

Bansi Loveleen, Smith Colette, Phillips Andrew, Kirk Stuart, Geretti Anna-Maria, Johnson Margaret, Mackie Nicola, Post Frank, Gazzard Brian, Dunn David, Sabin Caroline

Abstract excerpt

BACKGROUND: We investigate changes made to therapy after a resistance test result and identify factors associated with switching regimen. METHODS: Patients receiving antiretroviral therapy (ART) who had a resistance test performed during 1998-2007 were included in the analysis. A switch was defined as starting at least two drugs/starting a drug from a class not previously experienced within 4 months of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Retroviral Agents
Share to Data Collection

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Drug Resistance, Viral

Share to HIV Infections

Share to Retreatment

Share to Viral Load

Source

Identifiers

PMID: 21297420
DOI: 10.1097/QAD.0b013e32834403a0

Genes

GSS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of HIV drug resistance testing on changes to treatment.PMID 21297420Read ↗

Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.Semantic proximity Read ↗

Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch.Semantic proximity Read ↗

Management of antiretroviral therapy for HIV infection: modelling when to change therapy.Semantic proximity Read ↗

Genotypic susceptibility score (GSS) and CD4+ T cell recovery in HIV-1 patients with suppressed viral load.Semantic proximity Read ↗

Virologic Outcomes of Switching to Dolutegravir Functional Monotherapy, or Functional Dual Therapy With Dolutegravir Plus A Non-cytosine Nucleoside Analog: A Retrospective Study of Treatment-Experienced, HIV-1 Infected PatientsSemantic proximity Read ↗

Low levels of HIV-1 drug resistance mutations in patients who achieved viral re-suppression without regimen switch: a retrospective study.Semantic proximity Read ↗

When to switch and what to switch to: strategic use of antiretroviral therapy.Semantic proximity Read ↗

When to switch for antiretroviral treatment failure in resource-limited settings?Semantic proximity Read ↗

Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment.Semantic proximity Read ↗

Extent of human immunodeficiency virus type 1 drug resistance as a predictor of virological failure after genotype-guided treatment switch.Semantic proximity Read ↗

Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES studySemantic proximity Read ↗

High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.